PP
LMAT icon

Paloma Partners’s LeMaitre Vascular LMAT Stock Holding History

Paloma Partners’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,881
Closed -$227K – 1451
2022
Q1 		$227K Buy
+4,881
New +$218K 0.01% 1323

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CRM
Cramer Rosenthal McGlynn Stamford, Connecticut $1.36B AUM 31.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's LMAT Position: Q2 2022 in Review

Paloma Partners sold out of LeMaitre Vascular (LMAT) in Q2 2022, closing a stake of 4,881 shares — an estimated $227K sold.

Paloma Partners first reported a position in LMAT in Q1 2022 and held it in 1 quarter. The position peaked at $227K in Q1 2022. 179 funds tracked by Wall St. Rank hold LMAT as of Q2 2022.

  • Paloma Partners reported no remaining LeMaitre Vascular position as of Q2 2022 after selling out during the quarter.
  • Paloma Partners sold 4,881 LeMaitre Vascular shares in Q2 2022, an estimated $227K.
  • Paloma Partners first reported a position in LeMaitre Vascular in Q1 2022 and held it in 1 quarter.
  • Paloma Partners's LeMaitre Vascular position peaked at $227K in Q1 2022.
  • 179 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.